CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment, 71109 [2016-24807]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 199 / Friday, October 14, 2016 / Notices
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2016–24843 Filed 10–13–16; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Service
Administration
CDC/HRSA Advisory Committee on
HIV, Viral Hepatitis and STD Prevention
and Treatment
Health Resources and Service
Administration (HRSA), Department of
Health and Human Services, (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with section
10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92–463), notice
is hereby given that a meeting is
scheduled for the Centers for Disease
Control and Prevention (CDC)/HRSA
Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and
Treatment. This meeting will be open to
the public. Information about the CDC/
HRSA Advisory Committee on HIV,
Viral Hepatitis and STD Prevention and
Treatment and the agenda for this
meeting can be obtained by contacting
LCDR Holly Berilla at (301) 443–9965 or
hberilla@hrsa.gov.
DATES: The meeting will be held on
November 16, 2016, from 8:30 a.m. to
5:00 p.m. and November 17, 2016, from
8:30 a.m. to 3:30 p.m.
ADDRESSES: This meeting will be held
in-person and offer virtual access
through teleconference and Adobe
Connect. The address for the meeting is
5600 Fishers Lane, Rockville, Maryland
20857, Room 5A02 (Pavilion). Parties
may access the teleconference by dialing
800–369–1193 and using the public
participant code: 7050725. Parties may
also access the meeting through Adobe
Connect (visual only) by using the
following URL: https://
hrsa.connectsolutions.com/CHAC_1116.
FOR FURTHER INFORMATION CONTACT:
Anyone requesting information
rmajette on DSK2TPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
14:29 Oct 13, 2016
Jkt 241001
regarding the CDC/HRSA Advisory
Committee on HIV, Viral Hepatitis and
STD Prevention and Treatment should
contact LCDR Holly Berilla, Public
Health Analyst, Division of Policy and
Data (DPD), HIV/AIDS Bureau (HAB),
HRSA, in one of three ways: (1) Send a
request to the following address: LCDR
Holly Berilla, Public Health Analyst,
DPD, HAB, HRSA, 5600 Fishers Lane,
09N164C, Rockville, Maryland 20857;
(2) call 301–443–9965; or (3) send an
email to hberilla@hrsa.gov.
SUPPLEMENTARY INFORMATION: The CDC/
HRSA Advisory Committee on HIV,
Viral Hepatitis and STD Prevention and
Treatment was established under
Section 222 of the Public Health Service
Act, [42 U.S.C. Section 217a], as
amended.
The purpose of the CDC/HRSA
Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and
Treatment is to advise the Secretary,
HHS; the Director, CDC; and the
Administrator, HRSA regarding
objectives, strategies, policies, and
priorities for HIV, viral hepatitis, and
other STDs; prevention and treatment
efforts including surveillance of HIV
infection, AIDS, viral hepatitis, and
other STDs, and related behaviors;
epidemiologic, behavioral, health
services, and laboratory research on
HIV/AIDS, viral hepatitis, and other
STDs; identification of policy issues
related to HIV/viral hepatitis/STD
professional eduction, patient
healthcare delivery, and prevention
services; Agency policies about
prevention of HIV/AIDS, viral hepatitis
and other STDs; treatment, healthcare
delivery, and research and training;
strategic issues influencing the ability of
CDC and HRSA to fulfill their missions
of providing prevention and treatment
services; programmatic efforts to
prevent and treat HIV, viral hepatitis,
and other STDs; and support to the
Agencies in their developoment of
responses to emerging health needs
related to HIV, viral hepatitis, and other
STDs.
During the November 16–17, 2016,
meeting, the CDC/HRSA Advisory
Committee on HIV, Viral Hepatitis and
STD Prevention and Treatment will
discuss and deliberate on areas for
evaluation by HRSA/HAB; expansion of
national viral hepatitis programs;
employment, housing, aging and
leadership initiatives geared to people
living with HIV/AIDS; and updates from
Committee workgroups. Agenda items
are subject to change as priorities
dictate.
Members of the public will have the
opportunity to provide comments. Oral
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
71109
comments will be honored in the order
they are requested and may be limited
as time allows. Requests to make oral
comments or provide written comments
to the CDC/HRSA Advisory Committee
on HIV, Viral Hepatitis and STD
Prevention and Treatment should be
sent to LCDR Holly Berilla, using the
address and phone number listed above
by November 1, 2016. The building at
5600 Fishers Lane, Rockville, MD
20857, requires a security screening on
entry. To facilitate access to the building
please contact LCDR Holly Berilla at the
address and phone number listed above.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify LCDR Holly Berilla at the address
and phone number listed above at least
10 days prior to the meeting.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2016–24807 Filed 10–13–16; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Deafness and
Other Communication Disorders;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; U01
Clinical Trial Review.
Date: November 4, 2016.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Kausik Ray, Ph.D.,
Scientific Review Officer, National Institute
on Deafness and Other Communication
Disorders, National Institutes of Health,
E:\FR\FM\14OCN1.SGM
14OCN1
]]>Agencies
[Federal Register Volume 81, Number 199 (Friday, October 14, 2016)]
[Notices]
[Page 71109]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-24807]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Service Administration
CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD
Prevention and Treatment
AGENCY: Health Resources and Service Administration (HRSA), Department
of Health and Human Services, (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), notice is hereby given that a meeting
is scheduled for the Centers for Disease Control and Prevention (CDC)/
HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and
Treatment. This meeting will be open to the public. Information about
the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD
Prevention and Treatment and the agenda for this meeting can be
obtained by contacting LCDR Holly Berilla at (301) 443-9965 or
hberilla@hrsa.gov.
DATES: The meeting will be held on November 16, 2016, from 8:30 a.m. to
5:00 p.m. and November 17, 2016, from 8:30 a.m. to 3:30 p.m.
ADDRESSES: This meeting will be held in-person and offer virtual access
through teleconference and Adobe Connect. The address for the meeting
is 5600 Fishers Lane, Rockville, Maryland 20857, Room 5A02 (Pavilion).
Parties may access the teleconference by dialing 800-369-1193 and using
the public participant code: 7050725. Parties may also access the
meeting through Adobe Connect (visual only) by using the following URL:
https://hrsa.connectsolutions.com/CHAC_1116.
FOR FURTHER INFORMATION CONTACT: Anyone requesting information
regarding the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and
STD Prevention and Treatment should contact LCDR Holly Berilla, Public
Health Analyst, Division of Policy and Data (DPD), HIV/AIDS Bureau
(HAB), HRSA, in one of three ways: (1) Send a request to the following
address: LCDR Holly Berilla, Public Health Analyst, DPD, HAB, HRSA,
5600 Fishers Lane, 09N164C, Rockville, Maryland 20857; (2) call 301-
443-9965; or (3) send an email to hberilla@hrsa.gov.
SUPPLEMENTARY INFORMATION: The CDC/HRSA Advisory Committee on HIV,
Viral Hepatitis and STD Prevention and Treatment was established under
Section 222 of the Public Health Service Act, [42 U.S.C. Section 217a],
as amended.
The purpose of the CDC/HRSA Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and Treatment is to advise the Secretary,
HHS; the Director, CDC; and the Administrator, HRSA regarding
objectives, strategies, policies, and priorities for HIV, viral
hepatitis, and other STDs; prevention and treatment efforts including
surveillance of HIV infection, AIDS, viral hepatitis, and other STDs,
and related behaviors; epidemiologic, behavioral, health services, and
laboratory research on HIV/AIDS, viral hepatitis, and other STDs;
identification of policy issues related to HIV/viral hepatitis/STD
professional eduction, patient healthcare delivery, and prevention
services; Agency policies about prevention of HIV/AIDS, viral hepatitis
and other STDs; treatment, healthcare delivery, and research and
training; strategic issues influencing the ability of CDC and HRSA to
fulfill their missions of providing prevention and treatment services;
programmatic efforts to prevent and treat HIV, viral hepatitis, and
other STDs; and support to the Agencies in their developoment of
responses to emerging health needs related to HIV, viral hepatitis, and
other STDs.
During the November 16-17, 2016, meeting, the CDC/HRSA Advisory
Committee on HIV, Viral Hepatitis and STD Prevention and Treatment will
discuss and deliberate on areas for evaluation by HRSA/HAB; expansion
of national viral hepatitis programs; employment, housing, aging and
leadership initiatives geared to people living with HIV/AIDS; and
updates from Committee workgroups. Agenda items are subject to change
as priorities dictate.
Members of the public will have the opportunity to provide
comments. Oral comments will be honored in the order they are requested
and may be limited as time allows. Requests to make oral comments or
provide written comments to the CDC/HRSA Advisory Committee on HIV,
Viral Hepatitis and STD Prevention and Treatment should be sent to LCDR
Holly Berilla, using the address and phone number listed above by
November 1, 2016. The building at 5600 Fishers Lane, Rockville, MD
20857, requires a security screening on entry. To facilitate access to
the building please contact LCDR Holly Berilla at the address and phone
number listed above. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify LCDR Holly Berilla at the address and
phone number listed above at least 10 days prior to the meeting.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2016-24807 Filed 10-13-16; 8:45 am]
BILLING CODE 4165-15-P
